<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Hemolytic, Aplastic, and Sickle Cell Anemias | Family Medicine Reference</title>
  <style>
    body {
      font-family: "Segoe UI", Tahoma, Geneva, Verdana, sans-serif;
      background-color: #f8f9fa;
      color: #212529;
      line-height: 1.6;
      margin: 40px;
    }
    h1, h2, h3 {
      color: #004085;
    }
    section {
      background: #ffffff;
      border-radius: 8px;
      box-shadow: 0 2px 5px rgba(0,0,0,0.1);
      padding: 25px;
      margin-bottom: 20px;
    }
    table {
      width: 100%;
      border-collapse: collapse;
      margin: 15px 0;
    }
    th, td {
      border: 1px solid #dee2e6;
      padding: 10px;
      text-align: left;
    }
    th {
      background-color: #e9ecef;
    }
    .source {
      font-size: 0.9em;
      color: #555;
    }
    a {
      color: #0069d9;
      text-decoration: none;
    }
    a:hover {
      text-decoration: underline;
    }
  </style>
</head>
<body>

  <h1>Hemolytic, Aplastic, and Sickle Cell Anemias</h1>

  <!-- ============================== -->
  <!-- SECTION 1: HEMOLYTIC ANEMIA -->
  <!-- ============================== -->
  <section>
    <h2>Hemolytic Anemia</h2>
    <p>
      <strong>Hemolytic anemia</strong> refers to premature destruction of red blood cells (RBCs), 
      resulting in shortened RBC lifespan and increased reticulocyte production. 
      Causes are classified as <strong>intrinsic (inherited)</strong> or <strong>extrinsic (acquired)</strong>.
    </p>

    <h3>Classification</h3>
    <table>
      <tr><th>Category</th><th>Examples</th><th>Mechanism</th></tr>
      <tr><td>Intrinsic (RBC defect)</td><td>G6PD deficiency, hereditary spherocytosis, sickle cell disease, thalassemia</td><td>Membrane, enzyme, or hemoglobin defect</td></tr>
      <tr><td>Extrinsic (external factor)</td><td>Autoimmune hemolytic anemia, microangiopathic (TTP/HUS/DIC), infections (malaria), mechanical (valves)</td><td>Immune or mechanical destruction</td></tr>
    </table>

    <h3>Key Laboratory Findings</h3>
    <ul>
      <li>↑ Reticulocyte count</li>
      <li>↑ Indirect bilirubin</li>
      <li>↑ LDH</li>
      <li>↓ Haptoglobin</li>
      <li>Peripheral smear: spherocytes, schistocytes, bite cells, or sickled cells (depending on cause)</li>
    </ul>

    <h3>Autoimmune Hemolytic Anemia (AIHA)</h3>
    <table>
      <tr><th>Feature</th><th>Warm AIHA</th><th>Cold AIHA</th></tr>
      <tr><td>Antibody</td><td>IgG</td><td>IgM</td></tr>
      <tr><td>Hemolysis Site</td><td>Extravascular (spleen)</td><td>Intravascular + extravascular</td></tr>
      <tr><td>Causes</td><td>SLE, CLL, drugs (penicillin, methyldopa)</td><td>Infections (Mycoplasma, EBV), cold exposure</td></tr>
      <tr><td>Direct Coombs</td><td>Positive (IgG)</td><td>Positive (C3 complement)</td></tr>
      <tr><td>Treatment</td><td>Corticosteroids → Rituximab → Splenectomy</td><td>Avoid cold, Rituximab, treat infection</td></tr>
    </table>

    <h3>G6PD Deficiency</h3>
    <ul>
      <li>X-linked enzyme defect → RBCs susceptible to oxidative stress.</li>
      <li>Triggered by infection, fava beans, or drugs (sulfa, dapsone, primaquine).</li>
      <li>Smear: "bite cells" and "Heinz bodies".</li>
      <li>Diagnosis: low G6PD enzyme activity (after acute episode resolves).</li>
      <li>Treatment: avoid triggers, supportive care during crisis.</li>
    </ul>

    <h3>Microangiopathic Hemolytic Anemia (MAHA)</h3>
    <p>
      RBC fragmentation from endothelial injury and microthrombi (e.g., TTP, HUS, DIC).  
      Schistocytes on smear are characteristic.
    </p>
    <ul>
      <li><strong>TTP:</strong> ADAMTS13 deficiency → treat with plasma exchange.</li>
      <li><strong>HUS:</strong> Shiga toxin (E. coli O157:H7) → supportive care.</li>
      <li><strong>DIC:</strong> Widespread coagulation activation → treat underlying cause.</li>
    </ul>

    <h3>Management Summary</h3>
    <ul>
      <li>Treat the underlying cause.</li>
      <li>Transfusion as needed (careful in AIHA).</li>
      <li>Folic acid supplementation.</li>
      <li>Glucocorticoids for immune-mediated types.</li>
      <li>Avoid oxidative drugs in G6PD deficiency.</li>
    </ul>
  </section>

  <!-- ============================== -->
  <!-- SECTION 2: APLASTIC ANEMIA -->
  <!-- ============================== -->
  <section>
    <h2>Aplastic Anemia</h2>
    <p>
      <strong>Aplastic anemia</strong> is bone marrow failure characterized by pancytopenia (↓ RBCs, WBCs, platelets) 
      and hypocellular marrow without infiltration or fibrosis.
    </p>

    <h3>Etiology</h3>
    <ul>
      <li><strong>Idiopathic/autoimmune</strong> (most common)</li>
      <li>Drugs: chloramphenicol, chemotherapy, NSAIDs, carbamazepine</li>
      <li>Radiation or toxins (benzene)</li>
      <li>Viral infections (EBV, parvovirus B19, hepatitis, HIV)</li>
      <li>Inherited syndromes (Fanconi anemia)</li>
    </ul>

    <h3>Clinical Features</h3>
    <ul>
      <li>Fatigue, pallor (anemia)</li>
      <li>Infections (neutropenia)</li>
      <li>Easy bruising, bleeding (thrombocytopenia)</li>
      <li>No splenomegaly (helps differentiate from other causes)</li>
    </ul>

    <h3>Diagnosis</h3>
    <ul>
      <li><strong>CBC:</strong> Pancytopenia with normal MCV.</li>
      <li><strong>Reticulocyte count:</strong> ↓.</li>
      <li><strong>Bone marrow biopsy:</strong> Hypocellular marrow replaced by fat.</li>
      <li>Exclude other causes (vitamin deficiency, leukemia, myelodysplastic syndrome).</li>
    </ul>

    <h3>Treatment</h3>
    <ul>
      <li>Remove offending agents or treat infection.</li>
      <li>Supportive: transfusions, antibiotics for neutropenia.</li>
      <li>Immunosuppressive therapy: antithymocyte globulin (ATG) + cyclosporine.</li>
      <li>Allogeneic stem cell transplantation (preferred in young patients with severe disease).</li>
    </ul>
  </section>

  <!-- ============================== -->
  <!-- SECTION 3: SICKLE CELL DISEASE -->
  <!-- ============================== -->
  <section>
    <h2>Sickle Cell Disease (SCD)</h2>
    <p>
      A hereditary hemoglobinopathy caused by a point mutation in the β-globin gene, leading to 
      production of <strong>HbS</strong>. Under deoxygenated conditions, HbS polymerizes → 
      RBC deformation (“sickling”) → vaso-occlusion and hemolysis.
    </p>

    <h3>Genotypes</h3>
    <ul>
      <li><strong>Sickle cell anemia (HbSS):</strong> homozygous; most severe form.</li>
      <li><strong>Sickle cell trait (HbAS):</strong> heterozygous; usually asymptomatic, normal life expectancy.</li>
      <li><strong>Compound heterozygotes:</strong> HbSC, HbSβ-thalassemia (variable severity).</li>
    </ul>

    <h3>Clinical Features</h3>
    <ul>
      <li>Chronic hemolytic anemia (fatigue, pallor, jaundice)</li>
      <li>Vaso-occlusive pain crises (bone pain, chest pain, abdomen)</li>
      <li>Dactylitis (hand-foot swelling in infants)</li>
      <li>Splenic sequestration, autosplenectomy (functional asplenia by age 6)</li>
      <li>Infections by encapsulated organisms (S. pneumoniae, H. influenzae)</li>
      <li>Acute chest syndrome: new pulmonary infiltrate + pain + hypoxia</li>
      <li>Stroke (especially in children), leg ulcers, priapism</li>
    </ul>

    <h3>Diagnosis</h3>
    <ul>
      <li><strong>Peripheral smear:</strong> sickled cells, target cells, Howell-Jolly bodies.</li>
      <li><strong>Hemoglobin electrophoresis:</strong> confirms presence of HbS.</li>
      <li><strong>Newborn screening:</strong> universal in many countries.</li>
    </ul>

    <h3>Management</h3>
    <ul>
      <li><strong>Hydroxyurea:</strong> increases HbF → reduces crises and need for transfusion.</li>
      <li><strong>Folic acid supplementation.</strong></li>
      <li><strong>Vaccination:</strong> pneumococcal, meningococcal, H. influenzae type B, influenza.</li>
      <li><strong>Prophylactic penicillin</strong> from 2 months to 5 years of age.</li>
      <li>Manage pain crises: IV fluids, oxygen, NSAIDs/opioids as appropriate.</li>
      <li>Blood transfusion for severe anemia or acute chest syndrome.</li>
      <li>Exchange transfusion for stroke or severe vaso-occlusive complications.</li>
      <li><strong>Curative:</strong> bone marrow transplantation (selected severe cases).</li>
    </ul>

    <h3>Complications</h3>
    <ul>
      <li>Stroke</li>
      <li>Chronic kidney disease</li>
      <li>Leg ulcers</li>
      <li>Pulmonary hypertension</li>
      <li>Avascular necrosis (femoral head)</li>
      <li>Retinopathy</li>
    </ul>
  </section>

  <p class="source">
    Sources:<br>
    <a href="https://www.amboss.com/us/knowledge/hemolytic-anemia" target="_blank">AMBOSS: Hemolytic Anemia</a><br>
    <a href="https://www.amboss.com/us/knowledge/g6pd-deficiency" target="_blank">AMBOSS: G6PD Deficiency</a><br>
    <a href="https://www.amboss.com/us/knowledge/aplastic-anemia" target="_blank">AMBOSS: Aplastic Anemia</a><br>
    <a href="https://www.amboss.com/us/knowledge/sickle-cell-disease" target="_blank">AMBOSS: Sickle Cell Disease</a>
  </p>

</body>
</html>
